Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -97.08% is in line with its 2-year average of -89.49%, around the middle of its 2-year range (-203.99%–-41.87%).
As of the fiscal period ended Tuesday, June 30, 2026. 46.96% below its 12-month average of -66.06%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -97.08%.
RETURN ON EQUITY (ROE)
-97.08%
RETURN ON EQUITY (ROE) AVG TTM
-66.06%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-46.96%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.35%
median of 344 covered companies
CURRENT VS SECTOR MEDIAN
-209.62%
vs the sector median at left
Alumis Inc.
Market Cap
$844.28M
Return on Equity (ROE)
-97.08%
TTM Avg
-66.06%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$837.43M
Return on Equity (ROE)
-37.38%
TTM Avg
-29.74%
3Y Avg
-41.86%
5Y Avg
-72.28%
Market Cap
$852.55M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$867.60M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$786.48M
Return on Equity (ROE)
-25.03%
TTM Avg
-10.49%
3Y Avg
-5.87%
5Y Avg
-23.97%
Market Cap
$903.13M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$780.95M
Return on Equity (ROE)
-16.56%
TTM Avg
0.55%
3Y Avg
-10.56%
5Y Avg
-13.37%
Market Cap
$776.24M
Return on Equity (ROE)
-31.97%
TTM Avg
-50.13%
3Y Avg
-87.97%
5Y Avg
-79.93%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $844.28M | -97.08% | -66.06% | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | -37.38% | -29.74% | -41.86% | -72.28% |
| Beta Bionics, Inc. (BBNX)vs › | $852.55M | -28.46% | -48.75% | -33.66% | -33.66% |
| Apnimed, Inc. (APMD)vs › | $866.15M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $867.60M | -33.06% | -24.59% | -41.17% | -18.72% |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | -25.03% | -10.49% | -5.87% | -23.97% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.13M | -24.02% | -108.12% | -89.93% | -68.76% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | -16.56% | 0.55% | -10.56% | -13.37% |
| Geron Corporation (GERN)vs › | $776.24M | -31.97% | -50.13% | -87.97% | -79.93% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -35.07% | -26.66% | -24.19% | -5.48% |
ROE
-97.1%
ROA
-78.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -97.08% |
| 2026-03-31 | -41.87% |
| 2025-12-31 | -80.76% |
| 2025-09-30 | -63.71% |
| 2025-06-30 | -46.88% |
| 2025-03-31 | -203.99% |
| 2024-12-31 | -113.12% |
| 2024-09-30 | -68.54% |
